Regulator of G-protein signaling 18 controls both platelet generation and function by Delesque-Touchard, N (author) et al.
Regulator of G-Protein Signaling 18 Controls Both
Platelet Generation and Function
Nathalie Delesque-Touchard1*, Caroline Pendaries1, Ce´cile Volle-Challier1, Laurence Millet1,
Ve´ronique Salel1, Caroline Herve´1, Anne-Marie Pflieger1, Laurence Berthou-Soulie2, Catherine Prades2,
Tania Sorg3, Jean-Marc Herbert1, Pierre Savi1, Franc¸oise Bono1
1 Early to Candidate (E2C), Sanofi, Toulouse, France, 2 SCP Biologics, Sanofi, Vitry-Sur-Seine, France, 3Department of Scientific Operations PhenoPro, Mouse Clinical
Institute (MCI), Strasbourg, France
Abstract
RGS18 is a myeloerythroid lineage-specific regulator of G-protein signaling, highly expressed in megakaryocytes (MKs) and
platelets. In the present study, we describe the first generation of a RGS18 knockout mouse model (RGS18-/-). Interesting
phenotypic differences between RGS18-/- and wild-type (WT) mice were identified, and show that RGS18 plays a significant
role in both platelet generation and function. RGS18 deficiency produced a gain of function phenotype in platelets. In
resting platelets, the level of CD62P expression was increased in RGS18-/- mice. This increase correlated with a higher level
of plasmatic serotonin concentration. RGS18-/- platelets displayed a higher sensitivity to activation in vitro. RGS18 deficiency
markedly increased thrombus formation in vivo. In addition, RGS18-/- mice presented a mild thrombocytopenia,
accompanied with a marked deficit in MK number in the bone marrow. Analysis of MK maturation in vitro and in vivo
revealed a defective megakaryopoiesis in RGS18-/- mice, with a lower bone marrow content of only the most committed MK
precursors. Finally, RGS18 deficiency was correlated to a defect of platelet recovery in vivo under acute conditions of
thrombocytopenia. Thus, we highlight a role for RGS18 in platelet generation and function, and provide additional insights
into the physiology of RGS18.
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Introduction
From the bone-marrow, where megakaryopoiesis and throm-
bopoiesis occur (i.e. proliferation, differentiation, migration,
maturation of megakaryocytes and proplatelets into platelets) to
injured tissue, where platelets get activated, there are many
signaling pathways largely dependent on G protein-coupled
receptors (GPCRs) involved. GPCRs are by far the most
extensively validated class of therapeutic targets. Over half of the
existing drugs currently on the market are GPCR ligands.
However, only a small fraction of these receptors are targeted by
drugs [1,2]. Drug discovery efforts for GPCR ligands have
traditionally focused on targeting the orthosteric binding site of the
receptors. One of the key issues in this regard is that the orthosteric
binding sites across members of a single GPCR subfamily are often
highly conserved, making it difficult to achieve high selectivity for
specific GPCR subtypes. During the last decade, the idea of
targeting allosteric sites – so called allo-targeting - as a novel
approach to GPCR drug discovery has become a predominant
approach [3]. Rather than targeting receptors directly, one could
modulate signaling cascades downstream of receptor activation.
It is now well recognized that the regulators of G protein
signaling (RGS) play essential roles in GPCR signaling [4]. RGS
proteins are a family of cellular proteins with a conserved RGS
domain (also called RGS-box) of about 120 amino-acid residues.
RGS proteins specifically interact with the a subunits of G
proteins, greatly enhance the intrinsic GTPase activities of Ga,
and accelerate the hydrolysis of GTP to GDP by Ga, thus
converting G proteins from a GTP-bound active state to a GDP-
bound inactive state and terminating G protein-mediated signaling
[5]. There are over 20 members in the mammalian RGS family.
Based on sequence similarities and features of structural domains,
they have been classified into 9 subfamilies [6]. In vitro and in vivo
studies have provided strong evidence supporting that RGS
proteins display remarkable specificity and selectivity in their
regulation of GPCR-mediated physiological events [7]. The
spatiotemporal-specific expression of RGS proteins and their
target components, as well as the specific protein-protein
recognition and interaction through their characteristic structural
domains and functional motifs, are continually emerging as
determinants for RGS selectivity and specificity. Recent research
data are converging to highlight RGS proteins as attractive targets
PLOS ONE | www.plosone.org 1 November 2014 | Volume 9 | Issue 11 | e113215
for the development of potential future therapeutics [8,9]. An
RGS inhibitor would be expected to enhance GPCR signaling,
and should do so in a tissue- or pathway-specific manner.
Modulating RGS activity would then be a useful therapeutic
strategy to control GPCR signaling in a unique way.
In 2001, several groups independently identified RGS18, and
all agreed that RGS18 expression appears to be relatively
restricted to bone marrow-derived cells [10–12]. RGS18 was
found abundantly and predominantly expressed in platelets and, to
a less extent in megakaryocytes (MKs) and leukocytes, but not in
erythrocytes. In addition to RGS18, human MKs also highly
express RGS16 [12,13]. RGS16 and RGS18 have their respective
transcripts upregulated during MK differentiation and RGS16
was shown to act as a negative regulator of CXCR4 signaling in
MKs [13]. However, in contrast to the restricted expression profile
of RGS18, RGS16 is widely expressed. The expression patterns of
RGS transcripts have been evaluated in platelets, and RGS18 was
found to have the highest expression level, followed by RGS6,
RGS10, and RGS16 [14–16]. The functional significance of RGS
proteins in platelets has recently been validated in a mouse model
expressing a serine to glycine substitution at position 184 in the a
subunit of Gi2, the G protein that couples to platelet P2Y12
receptors for ADP [17]. The mutant Gai2 was shown to be unable
to interact with RGS, and loss of Gai2: RGS interactions
produced a gain of function in platelet activation. Most platelet
agonists (thrombin, ADP, TXA2 …) activate members of the
GPCR family, making G proteins and RGS proteins logical targets
for regulation. On the basis of the abundant and specific
expression pattern of RGS18 in platelets and MKs, we hypoth-
esized that it might be a key regulator of GPCR signaling in these
cells and to address this question, we have generated and
phenotyped mice lacking a functional RGS18 gene.
Here we report that RGS18 deficiency produces a pro-
thrombotic phenotype in mice, shifting the dose-response curve
for platelet aggregation induced by thrombin to the left in vitro
and increasing thrombus formation at sites of arteriovenous shunt
in vivo. Moreover, we also show that RGS18 deficiency is
sufficient to prime platelet activation even before an agonist is
added. In addition, RGS18-/- mice present a mild thrombocyto-
penia, accompanied by a reduced number of megakaryocytes
(MK) in their bone marrow. Analysis of MK maturation in vitro
and in vivo reveals that RGS18-/- mice display a defective
megakaryopoiesis. Finally, RGS18 was shown to display a
thrombocytopoietic activity, as revealed by deficient platelet
recovery in RGS18-/- mice under acute thrombocytopenia
conditions.
Methods
Generation of RGS18 mutant mice
RGS18 knockout mice were generated at the MCI (Mouse
Clinical Institute/Institut Clinique de la Souris, Strasbourg,
France). The targeting vector was constructed as described
follows: a 1kb PCR fragment encompassing exon 4 was cloned
(PCR done on embryonic stem (ES) cell genomic DNA 129S2/
SvPas genetic background) into an MCI proprietary vector,
resulting in step 1 plasmid. This MCI vector has a floxed
neomycin resistance cassette. Two PCR fragments of 4.2 kb
corresponding to the 59 homologous arm and 3 kb corresponding
to the 39 homologous arm were amplified and cloned successively
into the step 1 plasmid to generate the final targeting construct.
The linearized construct was electroporated into 129S2/SvPas
mouse ES cells. After selection, targeted clones were identified by
PCR using external primers and further confirmed by Southern
blot with 59 and 39 external probes. The positive ES clones were
injected into C57BL/6J blastocysts, and male derived chimeras
gave germline transmission. First L3 mice were successively bred
with Flp and Cre transgenic mice (on C57BL/6 genetic
background) to generate heterozygous mice with a deleted
neomycin cassette and an inactivated RGS18 locus. Mice were
then backcrossed for 4 consecutive generations to C57BL/6J
genetic background. Deletion of exon 4 was confirmed at the DNA
and transcript level.
Animals
C57BL/6J mice (Charles River Laboratories, Wilmington, MA,
USA) weighing between 27 to 34 g were used throughout the
study. The animals were kept on standard diet ad libitum and had
free access to tap water. For the length of the experiment, the
animals were maintained at an external temperature of 21uC +/
210%. The housing air was changed 15 to 20 times per hour. The
animals were used after one week of quarantine. This protocol was
approved by the "Comite´ d’Ethique Pour les Animaux de
Laboratoire" (Animal Care and Use Committee) of Sanofi R&D.
In silico analysis of RGS18 promoter
The RGS18 promoter sequence (from 21000 bps to +100 bps)
of human, mouse, rat, cow and dog were taken from Ensembl.
Sequences were aligned and analyzed for phylogenetic conserved
transcription factor binding sites (TFBS) using MatInspector and
frameWorker programs from Genomatix software suite.
Peripheral blood cell counting
Mice were anesthetized by using isoflurane gas (Aerrane;
Baxter, Lessines, Belgium). Peripheral blood samples were
obtained from the retro-orbital plexus with 75 mm EDTA
capillary tubes (Sarstedt, Montreal, Canada). Complete blood cell
counts were performed with the VetABC animal cell counter
(Horiba ABX SAS, Montpellier, France).
von Willebrand factor (vWF) staining on bone marrow
sections
Femora were fixed in formalin, decalcified in Dc3 (Labonord,
Temple-mars, France) and embedded in paraffin. Sections (5 mm)
were deparaffined, rehydrated through serially diluted ethanol
solutions to distilled water. After trypsin (Invitrogen, Carlsbad,
CA, USA) treatment (10 minutes at 37uC), immunohistochemistry
was performed using the Autostainer (Dako, Carpinteria, CA,
USA). Endogenous peroxidase activity was quenched with 3%
(wt/vol) hydrogen peroxide, and the sections were blocked with
10% (vol/vol) normal goat serum. The von Willebrand factor
(Dako) staining (12.4 mg/ml) was carried out with a standard 3-
stage immunoperoxidase method using the Vectastain Elite ABC
peroxidase kit (Vector Laboratories, Peterborough, UK). Diami-
nobenzidine was used as chromogen. Counterstaining was
performed with hematoxylin. For each section, the surface of the
bone marrow was measured with the 4x objective (Nikon Eclipse
E800) and the number of positive vWF MKs was counted using
the 20x objective. Morpho Expert software (Explora Nova, La
Rochelle, France) was used for the quantification.
Flow cytometric analysis
Blood samples were collected by retro-orbital puncture on
hirudin at the final concentration of 20 mg/ml. Cells were
incubated with FITC rat anti-mouse CD41 (BD Biosciences,
San Jose, CA, USA; 100 ng/ml) or with FITC rat anti-mouse
CD42b (Emfret Analytics, Eibelstadt, Germany; diluted to 1:5) for
RGS18 Controls Platelet Generation and Function
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10 minutes at room temperature. To measure basal platelet
activation, cells were stained with rat anti-mouse P-Selectin
(Emfret; diluted to 1:5) for 10 minutes at 37uC. After staining,
cells were fixed with Cellfix (BD Biosciences) according to the
manufacturer’s instructions, and analyzed with CyanADP cytom-
eter (Dako). MKs and platelets were discriminated according to
their forward and side scatter parameters. To quantify splenic
MKs and platelets, cells were isolated by homogenization of mice
spleen in IMDM medium containing 2% heat-inactivated FBS
using the Ribolyzer instrument (Hybaid, Teddington, UK). 100ml
of the homogenate were stained and red blood cells were lysed
with EasyLyse reagent (Dako) before cytometer analysis.
In vitro colony assays
Mice were lethally injected intraperitoneally with sodium
pentobarbital (150 mg/kg). Bone marrow cells were flushed from
femora and tibias with IMDM medium containing 2% heat-
inactivated FBS. Single-cell suspensions were prepared under
sterile conditions and enriched for Lineage-depleted (Lin-) cells
using a Spin Sep mouse hematopoietic progenitor negative
selection kit (StemCell Technologies, Vancouver, Canada). Lin-
marrow cells (5.104) were then cultured in double chamber slides
with Mega-Cult-C media (StemCell Technologies) in presence of
rmIl-3 (Peprotech, Rocky Hill, NJ, USA; 10 ng/ml), rmIl-6
(Peprotech; 3 ng/ml) and rhTPO (Peprotech; 50 ng/ml). After 11
days of culture, the slides were dehydrated and colonies were
stained with FITC rat anti-mouse CD41 (BD Biosciences). Slides
were scored microscopically, and MK colonies (CFU-MKs) were
defined as colonies with at least 3-4MKs.
Ploidy analysis of CD41+ bone marrow megakaryocytes
Bone marrow suspensions were prepared in a phosphate-
buffered saline (PBS)-bovine serum albumin (BSA) buffer (PBS
containing 0.5% BSA). Cells (5.106) were labeled for 30 min at
4uC with 1.25 mg of a fluorescein isothiocyanate (FITC)-conjugat-
ed monoclonal antibody against CD41 (rat anti-mouse glycopro-
tein IIb; Pharmingen) and gently washed twice in PBS-BSA. The
pellet was resuspended in 200 ml of PBS and 4 ml of a cold
solution of 70% ethanol in PBS was added. After incubation for
1 h at 4uC, the suspension was centrifuged, the cells were
resuspended in 100 ml of PBS and propidium iodide (Sigma-
Aldrich, Gillingham, UK; 2 mL [50 mg/mL]) and RNAase
(Sigma; 100 mg/ml) in PBS were added for 30 min at 37uC.
The ploidy distribution in the CD41+ population was determined
by two-color flow cytometry (BD FACSCanto; BD Biosciences).
Platelet depletion
Mice were given a sterile intraperitoneal injection of anti-mouse
Gp1ba (Emfret; 2mg/g). 4 hours later, mice were tailed bled to
determine baseline blood cell count. Then, platelet count was
measured at 48, 72, 96, and 168 hours post injection by retro-
orbital sampling.
Thrombocytopenia was also produced by the intraperitoneal
injection of busulfan (Myleran; Burroughs-Wellcome, Research
Triangle, NC, USA). Busulfan was injected to mice intraperito-
neally at 30 mg/kg (in a 25% polyethylene glycol-400 solution) at
day 0. Platelet counts were performed following the same
procedure as described earlier at days 7, 11, 15, and 24.
Platelet Clearance
Mice platelets were biotinylated in vivo by infusion with NHS-
biotin (Calbiochem, La Jolla, CA, USA). 10 mg NHS-biotin/kg
body weight were dissolved in DMSO, then diluted into sterile
saline solution at 1 mg/ml. The solution was slowly injected via
the lateral tail vein of mice with a 26G1/2 needle. Blood collection
was realized by retro-orbital sampling at days 1, 2, 3, 4 and 7 after
biotin injection. Samples were stained with FITC rat anti-mouse
CD41 (BD Biosciences; 100 ng/ml) and then incubated with PE-
Streptavidin (Calbiochem; diluted to 1:3). The platelet biotinyla-
tion rate was analyzed by flow cytometry (CyanADP, FITC
staining).
Platelet-rich Plasma (PRP) Preparation
Venous blood was collected into tubes containing a 3.8%
trisodium citrate solution (9:1 vol/vol). Platelet-rich plasma (PRP)
was obtained by centrifuging blood samples at 2006g for 10 min
and left for 30 min at 37uC prior to stimulation.
Serotonin release assay
An aliquot of PRP was centrifuged at 20006g for 10 min to
obtain platelet-free plasma (PFP). 100 ml of PFP were used in the
serotonin ELISA kit (Labor Diagnostika Nord Gmbh, Nordhorn,
Germany) for the measurement of free (not bound to platelets)
serotonin according to the manufacturer’s instructions.
aIIbb3 Activation
Platelet activation was determined according to the method of
Bergmeier [18]. Platelets in PRP were stimulated at 37uC for
3 minutes using ADP (2.5 mM), collagen (10 mg/ml), or increasing
doses of TRAP (125 mM-500 mM). Platelets were then stained with
JON/A-PE32 (Emfret Analytics, Wuerzburg, Germany) for
10 minutes at room temperature and analyzed by flow cytometry.
Aggregometry
Platelet aggregation was determined according to the Born
method [19] on a dual-channel Chrono-Log aggregometer
(Chrono-log, Havertown, PA, USA). The experiment was
performed at 37uC under constant stirring conditions
(1200 rpm). Increasing concentrations of thrombin (0.01–1 UI/
ml) were added to PRP and light transmission was recorded over
6 minutes.
Silk thread arterio-venous shunt model
Two 6 cm-long polyethylene tubing (0.28 and 0.61 mm inner
and outer diameter, respectively) linked to a central part (3 cm-
long; 0.58 and 0.96 mm inner and out diameter, respectively)
containing a 3 cm-long silk thread and filled with saline solution
were placed between the right carotid artery and the left jugular
vein in anaesthetized animals (xylazine 20 mg/kg + ketamine
100 mg/kg ip). The central part of the shunt was removed after
10 minutes of blood circulation and the silk thread carrying the
thrombus was pulled out. The wet weight of the thrombus was
determined.
Experimental tail transection bleeding model
Mice were anesthetized by intraperitoneal injection of xylazine
(20 mg/kg) with ketamine (100 mg/kg). The bleeding time was
determined according to Dejana et al. [20] adapted for mice, by
transection of the tail 2 mm from the tip. Blood was carefully
blotted on a filter paper every 15 sec during the two first minutes
and every 30 sec thereafter. The observation period was limited to
45 minutes. Hemostasis was considered to be achieved when no
more bloodstaining was observed over 1 min. Raw data corre-
spond to the bleeding time in minutes.
RGS18 Controls Platelet Generation and Function
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Statistical analysis
Results are presented as means 6 SD. The data were analyzed
by using a 1-way analysis of variance (ANOVA) with Student t test
or Dunnett test. P values less than .05 were considered to be
statistically significant.
Results
Generation of RGS18 mutant mice
To determine the role of RGS18 in vivo, RGS18 mutant mice
were generated. In order to disrupt the RGS18 gene by
homologous recombination in ES cells, a targeting vector was
designed, with a selectable neomycin resistance cassette (Figure
S1). After electroporation of the targeting vector into 129S2/SvPas
ES cells, several independent clones exhibiting the expected
homologous disruption of RGS18 were used to generate chimeric
mice by blastocyst injection (see Materials and Methods). Chimeric
males were used for germline transmission of the targeted RGS18
allele. Adult mice carrying disrupted alleles of the RGS18 gene
were viable, healthy, and displayed no visible physical abnormal-
ities. The production colony provided normal ratios of WT and
knockout males and females. The MCI performed the phenotype
analysis of RGS18-/- mice; the metabolic or functional assess-
ments performed are described in the ‘‘Information S1’’
document: metabolic exploration (Table S1), cardiovascular
investigations (Table S2), necropsy and histological analysis (Table
S3), and behavioral characterization (Table S4). No significant
difference was observed between WT and RGS18-KO mice (data
not shown), except during behavioral phenotyping where mutant
mice displayed behavior that could be interpreted as an increase in
reactivity/anxiety and increased pain sensibility (see Table S5,
Figure S2 and Figure S3).
In silico analysis of RGS18 promoter
To further characterize RGS18 function, an in silico prediction
of regulatory elements in the proximal promoter region was
performed. 18 transcription factor binding sites conserved in at
least 4 species were identified, and 11 of them are described as
regulators of hematopoietic gene expression. More specifically,
within the 200 bps from the transcriptional start site, 5 cis-
regulatory elements corresponding to transcription factors, known
to play a role in the development of hematopoietic cell lineages,
were found (Figure S4). These binding sites correspond to the
transcription factor GATA1, described as essential for erythroid
and megakaryocyte development; RUNX1, (located close to
GATA1) whose collaboration with GATA1 is required for
megakaryocyte differentiation [21]; EVI1, frequently found in
myeloid leukemias and whose expression is also associated with
progression of megakaryocyte differentiation [22]; STAT3, which
among its numerous diverse gene functions has been described to
play a role in early stage of megakaryopoiesis too [23]; and
MEIS1, known to play an important role in megakaryocytic-
specific genes [24]. The identification of these predicted regulatory
elements, associated with their co-localisation in the proximal
promoter of RGS18 suggests a possible regulation of its gene
expression during megakaryopoiesis.
Mice lacking RGS18 present a mild thrombocytopenia
Analysis of peripheral blood samples of RGS18-/- mice and
normal littermates for their hematologic profile showed that
RGS18-/- mice were moderately thrombocytopenic: a mean of
,15% reduction in platelet counts was observed in RGS18-/-
mice with respect to WT mice (Table 1). All other blood
parameters analyzed, including red blood cells and total white
blood cells, were normal in RGS18-/- mice. Interestingly, the
mean platelet volume was significantly increased from an average
of 4.94 mm3 in WT mice to 5.05 mm3 in RGS18-/- mice. These
data suggested that RGS18 might be implicated in megakaryopoi-
esis/thrombopoiesis.
One of the direct causes of thrombocytopenia is a reduction in
the number of megakaryocytes (MK) in the bone marrow. We
therefore examined MK counts in femora after staining of bone
marrow sections for Von Willebrand Factor, a sensitive marker for
identification of marrow MKs [25]. As shown in Figure 1, the
number of MKs per mm2 was markedly decreased in RGS18-/-
mice.
In mice, in addition to bone marrow, the spleen is an important
alternative hematopoietic organ. Indeed, MKs rarely appear in the
spleen of normal adult mice, but are often found in the spleen
when megakaryopoiesis in bone marrow is disrupted [26,27].
Therefore, we also examined the number of splenic MKs in
RGS18-/- mice. Although MK counts were slightly increased in
the spleens of RGS18-/- mice (0.8760.07, n= 6, in RGS18-/-
mice versus 0.7260.08, n = 6, in WT mice), the difference was not
found to be statistically significant (Figure S5).
Table 1. Peripheral blood cell counts in WT and RGS18-/- mice.
WT RGS18-/- P values
Platelets 1291.3 1119.1 ,0.0001 (***)
MPV 4.94 5.05 0.0031 (**)
Red Blood cells 9.53 9.71 NS
White Blood cells 8.65 9.07 NS
Lymphocytes 6.054 6.496 NS
Monocytes 0.35 0.37 NS
Granulocytes 2.24 2.2 NS
Blood collected by retro-orbital venous puncture was analyzed in a VetABC animal cell counter. All counts are thousands per microliter, except for red blood cells which
are millions per microliter. *P,.05; **P,.01; ***P,.001.
doi:10.1371/journal.pone.0113215.t001
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Defective megakaryopoiesis in RGS18-/- mice
To further characterize megakaryopoiesis in the absence of
RGS18, MK progenitor cells from bone marrow of RGS18-/- and
WT mice were first assayed in clonogenic culture. In vitro colony
assays in presence of a cocktail of cytokines regulating mega-
karyopoiesis showed that the number of MK progenitors (CFU-
Meg) was clearly higher in WT mice than in RGS18-/- mice
(Figure 2A), indicating that RGS18 deficiency in MK progenitors
affects their in vitro maturation potential.
To confirm these results, we next examined the in vivo
maturation potential of bone marrow MKs. Bone marrow cells
were stained for CD42b and MKs were identified by flow
cytometry. We observed that the level of MKs from bone marrow
of WT mice was in accordance with litterature data (,1%).
However, the percentage of MKs was significantly decreased in
RGS18-/- mice (Figure 2B), as previously observed in the
histologic analysis of bone marrow sections.
Finally, we analyzed the ploidy distribution of bone marrow
MKs. Ploidy, a distinctive characteristic of differentiated MKs, was
measured by flow cytometry using propidium iodide fluorescence.
Interestingly, we found that the frequency of early MK progenitors
with 2N DNA content in RGS18-/- mice was similar to that of
WT mice, while the proportion of more committed MK
precursors with .2N DNA content was markedly decreased in
RGS18-/- mice (Figure 2C), indicating a direct correlation
between RGS18 and MK maturation.
RGS18 deficiency induces a defect in platelet generation
after acute thrombocytopenia
To evaluate the involvement of RGS18 in thrombocytopoietic
activity in vivo, experiments of acute thrombocytopenia were
conducted in RGS18-/- mice and their normal littermates. In the
first model, a complement-mediated immune thrombocytopenia
was induced by an intraperitoneal injection of an anti-mouse GpIb
antibody, based on the method of Nieswandt et al. [28]. As shown
in Figure 3A, GpIb antibody injection led to a dramatic decrease
(.95%) in platelet counts within 4 hours in RGS18-/- and WT
mice. Platelet recovery was measured at 48 h, 72 h, 96 h, and
168 h post-injection. As previously observed, recovery of platelet
counts was achieved between 96 h and 168 h, and a defective
platelet recovery was clearly observed in RGS18-/- mice
(Figure 3A).
In the second model of thrombocytopenia, mice were
myelosuppressed by intraperitoneal injection of busulfan, a cancer
chemotherapy agent. The busulfan-treated mice showed platelet
nadir around day 11, and then the platelet number gradually
recovered to approximately 100% by day 24 in WT mice
(Figure 3B). RGS18-/- mice showed a lower platelet number at
the nadir and a significantly reduced platelet recovery over the
experimental period compared to WT mice (Figure 3B).
RGS18-/- mice display a platelet destructive disorder
In addition to a defective platelet production by the bone
marrow, thrombocytopenia could also reflect an increased rate of
platelet removal from the blood. Abnormalities in different
processes can lead to this, i.e. increased trapping of platelets by
the spleen, diminished platelet survival, or platelet consumption.
Thus, we first examined if the observed thrombocytopenia in
RGS18-/- mice could be caused by a splenic sequestration of the
platelets. As shown in Figure 4A, the spleens of the RGS18-/-
mice did not contain an increased number of platelets. Platelet
counts were significantly decreased compared with those of the
WT mice (p = 0.031), in a parallel with the respective number of
circulating platelets in WT and RGS18-/- mice. We consistently
did not observe any splenomegaly in the RGS18-/- mice (data not
shown).
To determine whether alterations in platelet half-life could
contribute to thrombocytopenia in mice lacking RGS18, in vivo
labeling studies of blood cells were performed by biotinylation.
Flow cytometry analysis revealed no difference in the rate of
platelet clearance from the circulation in RGS18-/- mice
compared to WT controls (Figure 4B), indicating that the lower
level of circulating RGS18-/- platelets is not the result of
diminished platelet survival.
Finally, we investigated whether platelets from RGS18-/- mice
could be consumed by spontaneous aggregation. Spontaneous
platelet aggregation (SPA) was evaluated by flow cytometry on
whole blood with no platelet agonists added. Analysis of
circulating platelet aggregates showed that the RGS18-/- mice
presented more spontaneous platelet aggregates than WT mice
(Figure 4C), suggesting that the observed thrombocytopenia in
RGS18-/- mice could be the reflect of both a defective
megakaryopoiesis and a spontaneously enhanced platelet aggreg-
ability.
Figure 1. Bone marrow MKs in RGS18-/- mice. (A) Representative
vWF immunostaining images of frozen femur sections from 9-week-old
WT and RGS18-/- mice. Positively stained MKs from 6 bone marrow
sections per mice (n = 3 per group) were scored under a microscope.
Images were obtained using ECLIPSE E800 microscope (Nikon, Tokyo,
Japan) equipped with a 4x objective (Nikon Eclipse E800). The number
of positive vWF MKs was counted by using the 20x objective. Morpho
Expert software (Explora Nova, La Rochelle, France) was used to acquire
and process images. (B) Cumulative analysis of the numbers of MKs per
square millimeter is shown. ***P,.001.
doi:10.1371/journal.pone.0113215.g001
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RGS18 deficiency induces a prothrombotic phenotype in
mice
To further investigate whether RGS18-/- mice could present
thrombogenic disorders, we first analyzed the basal platelet
activation state by measuring platelet activation markers. Seroto-
nin has been shown to play a central role in the haemostatic
process, and its release is considered to be the most reliable
biological assay for platelet activation [29]. The quantitative
determination of serotonin in plasma by enzyme immunoassay
measurement showed increased levels in RGS18-/- mice, with
concentrations being approximately 53% higher than those
measured from plasma samples of the WT mice (Figure 5A).
CD62P (P-selectin) is a constituent of alpha granules and is
released to the platelet surface upon activation, a process parallel
to secretion of serotonin [30]. Basal platelet activation was thus
assessed by flow cytometry on whole blood measuring surface
CD62P expression with no platelet agonists added. Figure 5B
shows a mean of ,54% increase in basal CD62P expression on
RGS18-/- platelets with respect to WT platelets, indicating that
RGS18 deficiency primes platelet activation even in the absence of
an added platelet agonist.
Figure 2. RGS18-/- mice present a defective megakaryopoiesis. (A) In vitro MK maturation. Lin- bone marrow cells (56104 cells/chamber) from
9/10-week-old WT and RGS18-/- mice (n = 5 per group) were cultured in Mega-Cult-C media containing 50 ng/mL rhTPO, 10 ng/ml rmIL3, and 3 ng/
ml rmIL6 in double-chamber slides at 37uC for 11 days. Slides were then dehydrated and stained with CD41. Slides were scored microscopically, and
MK colonies (CFU-MKs) were defined as colonies containing at least 3-4MKs. (B) In vivo MK maturation. Bone marrow cells from 9-week-old WT and
RGS18-/- mice (n = 6 per group) were stained for CD42b, and MKs were identified by flow cytometry on the basis of size and CD42b positivity.
Percentages of total bone marrow cell population are shown. (C) MK ploidy analysis. Bone marrow cells from 9-week-old WT and RGS18-/- mice (n = 6
per group) were stained for CD41 in presence of propidium iodide (PI). MKs were identified by flow cytometry on the basis of size and CD41 positivity.
DNA cell content was evaluated on the basis of PI fluorescence intensity. Percentages of total bone marrow cell population with DNA content .2N
are shown. *P,.05; **P,.01; ***P,.001.
doi:10.1371/journal.pone.0113215.g002
RGS18 Controls Platelet Generation and Function
PLOS ONE | www.plosone.org 6 November 2014 | Volume 9 | Issue 11 | e113215
By analyzing basal and TRAP-activated platelets using 2-DE gel
electrophoresis, RGS18 has recently been found to be phosphor-
ylated on Ser49 in response to TRAP activation [31]. To
determine whether RGS18 could also regulate PAR signaling in
platelets, we next examined the platelet activation responses to
TRAP and thrombin in WT and RGS18-/- mice. Platelet
activation was assessed by flow cytometry measuring surface
expression of activated integrin aIIbb3. As shown in Figure 5C,
murine TRAP (PAR-4 peptide activator) dose-dependently
induced an activation-dependent conformational change in
integrin aIIbb3 on platelets from WT littermates, and an
enhanced response was observed in RGS18-/- mice as early as
the concentration of 0.25 mM of mTRAP. Similarly, the response
to thrombin was found to be increased in RGS18-/- mice, as
assessed using in vitro platelet aggregation assays (data not shown).
RGS18-/- mice show enhanced platelet function in vivo
Platelets are known to play a central role in both arterial and
venous thrombosis. To determine whether RGS18 deficiency
affects platelet function in vivo, we used the silk thread arterio-
venous shunt thrombosis model, which has been characterized as a
‘‘mixed’’ thrombosis model in rats [32]. In this model, both the
activation of platelets (often linked to arterial thrombosis) and the
coagulation cascade (commonly associated with venous thrombo-
sis) are known to contribute to the thrombus formation. Since
RGS18-/- platelets displayed an enhanced basal aggregability,
thrombus formation was measured after a very short time of blood
circulation. Analysis of thrombus weight after a 5 min-blood flow
Figure 3. RGS18-/- mice present a defective thrombopoiesis
after acute thrombocytopenia. (A) Complement-mediated immune
thrombocytopenia. 10-week-old WT (n = 8; black circle) and RGS18-/-
mice (n = 8; open circle) were given a sterile intraperitoneal injection of
anti-mouse aGpIb antibody (2 mg/g of mouse) at T0 (Arrow). Platelet
counts were measured at 4, 48, 72, 96, and 168 hours after injection. (B)
Busulfan-induced thrombocytopenia. Busulfan was injected to 9/13-
week-old WT (n = 15; black circle) and RGS18-/- mice (n = 14; open circle)
intraperitoneally at 30 mg/kg (day 0; arrow). Platelet counts were
measured at 7, 11, 15, and 24 days after injection. *P,.05; **P,.01;
***P,.001.
doi:10.1371/journal.pone.0113215.g003
Figure 4. Rate analysis of platelet removal from blood. (A)
Splenic sequestration of platelets. Crushed spleens from 9/13-week-old
WT and RGS18-/- mice (n = 6 per group) were stained for CD42b, and
platelets were identified by flow cytometry on the basis of size and
CD42b positivity. Percentages of total splenic cell population are
shown. (B) Clearance of platelets. Blood cells from 7-week-old mice
were biotinylated in vivo by infusion of NHS-biotin, and then blood
samples were collected at the time indicated. Biotinylated platelets
from WT (black line) and RGS18-/- (red line) mice (n = 9 per group) were
identified by flow cytometry on whole blood using PE-Streptavidin and
CD41 staining. The stability of the biotinylation was assessed by
examining the in vivo biotinylated CD41- blood cells in WT (green line)
and RGS18-/- (yellow line) mice (n = 9 per group). (C) Spontaneous
platelet aggregation. Whole blood cells from 9/11-week-old WT and
RGS18-/- mice (n = 12 per group) were stained for CD42b, and platelets
were identified by flow cytometry on the basis of size and CD42b
positivity. Platelet aggregates were monitored by extending the
platelet gate so as to include the platelet ‘‘smearings’’ having elevated
FSC and FITC fluorescence. Percentages of total cell population are
shown. *P,.05; **P,.01.
doi:10.1371/journal.pone.0113215.g004
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showed that RGS18 deficiency markedly increased platelet
accumulation, with thrombi being more than 2 times larger in
RGS18-/- mice than those of WT mice (Figure 6).
In agreement with the prothrombotic phenotype of the
RGS18-/- mice, there was no evidence of spontaneous bleeding
in these mice (data not shown).
Discussion
RGS18 has been described in 2001 as a myeloerythroid lineage-
specific regulator of G-protein signaling, highly expressed in MKs
and platelets. Several studies report that the RGS18 transcript is
specifically detected in haematopoietic progenitor and myeloery-
throid lineage cells, and that they are most highly abundant in
MKs and platelets [10–12]. In accordance with this expression
pattern, our results show that RGS18 is important for MK biology
and that RGS18 deficiency produces a defective megakaryopoi-
esis, affecting the maturation potential of MK progenitors in vitro
as well as in vivo. Moreover, RGS18 deficiency induces a chronic
thrombocytopenia in mice and a defect in platelet recovery and
formation after acute thrombocytopenia. Together, these results
Figure 5. RGS18 deficiency induces a prothrombotic phenotype in mice. (A) Serum levels of serotonin. Blood from 10-week-old WT and
RGS18-/- mice (n = 9 per group) was collected, and the quantitative determination of serotonin in serum was performed by enzyme immunoassay
(ELISA). Concentrations of serotonin (ng/ml) are shown. (B) P-selectin (CD62P) expression on platelets. Whole blood cells from 12-week-old WT and
RGS18-/- mice (n = 6 per group) were stained for CD62P, and platelets were identified by flow cytometry on the basis of size and CD42b positivity.
Fluorescence intensities of platelet CD62P are shown. (C) Platelet activation in response to TRAP. Platelet-rich plasma (PRP) from 9/11-week-old WT
and RGS18-/- mice (n = 6 per group) was prepared, and incubated at 37uC during 3 minutes with different concentrations of TRAP (mM). Platelet
activation was measured by flow cytometry detection of activated integrin aIIbb3. Percentages of platelet activation are shown. *P,.05; ***P,.001.
doi:10.1371/journal.pone.0113215.g005
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suggest that RGS18 plays a physiological role in hematopoiesis, in
particular taking an active part in megakaryopoiesis and platelet
generation. It is interesting to note that Louwette and colleagues
recently reported that lentiviral RGS18 overexpression during in
vitro differentiation of mouse Sca1+ hematopoietic stem cells
induced an increase in MK proliferation and that RGS18
depletion in zebrafish resulted in thrombocytopenia [33].
In 2005, Berthebaud and colleagues proposed that RGS16
might be a negative regulator of SDF-1/CXCR4 signaling in MKs
[13]. They observed that overexpression of RGS16, but not of
RGS18, in MO7e cells inhibited SDF1-induced migration, and
down-regulation of RGS16 by RNA interference in MO7e cells
and in primary MKs promoted SDF1-induced chemotaxis. In
contrast with their results obtained with RGS18, we did indeed
observe a functional role of RGS18 in MK migration (Figure S6).
Actually, RGS18 downregulation by RNA interference in Dami
cells comes with an increase of SDF1-induced Dami cell
migration. The apparent discrepancy between these two sets of
results could arise not only from the use of different megakaryo-
blastic cell lines, but also from the different technical strategies
used to evaluate the role of RGS18 in MK cell migration – namely
RGS18 overexpression versus silencing. To date, RGS18 expres-
sion levels in MK cells have been always reported to be strong and
much higher than RGS16 expression levels [12,13,15]. Therefore,
overexpressing RGS18 in cells where its expression level is already
very strong might not be the most appropriate approach for
observing subsequent effects. Furthermore, our results are well
supported by a study from Nagata and colleagues who found that
SDF-1 binding to its receptor CXCR4 affected the binding
capacity of RGS18 to Gai, but not Gaq, in MKs [10]. Based on
these different observations, RGS18 might control MK migration
to regulate megakaryopoiesis by attenuating CXCR4 signaling,
suggesting that a functional redundancy among RGS16 and
RGS18 might exist in MKs.
RGS1, 2, 3, 6, 9, 10, 16, 18, and 19 transcripts are shown to be
detected in human platelets [14] and RGS2, 3, 5, 6, 10, 14, 16,
and 18 transcripts are present in rat platelets [15]. At the protein
level, only RGS10 and RGS18 have been detected in human
platelets [31,34]. Functionally, these two RGS proteins have been
found: (a) to be differentially phosphorylated after TRAP
stimulation of platelets [31], (b) to be associated with spinophilin
(SPL) in resting platelets [34], and (c) to be released from SPL after
platelet activation by thrombin [34]. Therefore, a functional
redundancy among RGS family members might exist in platelets.
At the bone marrow level, mRNA transcripts of RGS1, 2, 8, 10,
12, 14, 16, 18, and 19 are detected in mice, and no difference in
their expression level is observed in extracts from either RGS18-
deficient mice and WT mice (Figure S7). Because RGS18-deficient
mice are viable, elucidating whether RGS10 partly compensates
for RGS18 function in our RGS18 knockout model is a question
that will need to be addressed.
In addition to the regulatory role of RGS18 in MK biology, our
results show that RGS18 deficiency produces a gain of function
phenotype in platelets, shifting the dose-response curve for platelet
aggregation induced by thrombin to the left in vitro and increasing
thrombus formation at sites of arteriovenous shunt in vivo.
Moreover, we also show that RGS18 deficiency is sufficient to
prime platelet activation even before an agonist is added.
Collectively, these observations show for the first time the
functional significance of RGS18 in platelets and suggest that its
physiological role is to limit platelet activation and accumulation
during thrombus formation.
In accordance with our results, Signarvic and colleagues
recently demonstrated the active role of RGS proteins in
regulating platelet responsiveness [17]. Platelets from mice with
a G184S substitution in Gia2 that blocks RGS/Gi2 interactions,
showed increased responsiveness to agonists in vitro and increased
accumulation after vascular injury in vivo. This increased
responsiveness was not limited to Gi2-coupled receptor agonists
such as ADP. Gia2 (G184S) substitution also produced increased
responses to PAR4 and TxA2 receptor agonists, although signaling
downstream of these receptors in platelets is usually attributed to
Gq and (to a lesser extent) G12 family members rather than to
direct activation of Gi family members. In contrast to these results,
we observe that RGS18 deficiency produces a pathway-selective
gain of function in platelets. RGS18-deficient platelets respond
significantly better than controls at low concentrations of either
thrombin (PAR-1 receptor agonist) or TRAP (PAR-4 receptor
agonist), whose receptors are both Gq-coupled receptors. On the
other hand, RGS18 deficiency does not produce a shift in the
dose-response curve for platelet aggregation induced by ADP
(Figure S8). The Gi-coupled P2Y12 receptor is the major ADP
receptor in platelets, and an increased response of RGS18-
deficient platelets at suboptimal ADP concentration is what would
be expected if RGS18 protein restrains this Gi-dependent
signaling pathway. In investigating possible changes induced by
RGS18 deficiency in platelet responsiveness not related to agonists
coupled to G-protein pathways, we also found no difference in
platelet aggregation induced by collagen between RGS18-deficient
and WT platelets (Figure S8). Thus, we can assume that RGS18
retains specificity for pathways known to be mediated by Gq and
does not spill over to predominantly Gi-driven events in platelets.
To further establish that RGS18 regulation of platelet function is
strictly confined to Gq-mediated events, it will be important to
evaluate its role in RGS18-deficient platelet responsiveness to
TxA2.
Nevertheless, our assumption is strongly supported by latest
results of Ma and colleagues who described an association of
spinophilin (SPL) with RGS18 in resting platelets and more
especially an agonist-selective dissociation of this complex during
platelet activation [34]. In their study, dissociation of the SPL/
RGS18 complex occurred when human platelets were incubated
with the two potent activators of Gq-mediated events, thrombin
and TxA2, but not in presence of ADP or collagen. Similarly, we
observed an increase of platelet responsiveness when RGS18-
deficient platelets are incubated with thrombin or TRAP, but not
Figure 6. RGS18 deficiency increases thrombus formation at
sites of arterio-venous shunt in vivo. An arterio-venous shunt was
achieved as described on 11/13-week-old WT and RGS18-/- mice (n = 14
per group) and thrombus weight was determined after 10 minutes of
blood circulation. *P,.05.
doi:10.1371/journal.pone.0113215.g006
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in presence of ADP or collagen. Both studies converge on the idea
that RGS18 might at least control PARs signaling. In 2004, Garcia
and colleagues had already observed that PAR receptor signaling
induced the phosphorylation of Serine 49 of RGS18 in platelets
[31]. More recently, Gegenbauer and colleagues also showed that
RGS18 is phosphorylated on S49 and S218 in platelets, and that
phosphorylation of S49 increased with platelet activation by
thrombin [35,36]. Furthermore, they also showed that RGS18
inhibited Gq-mediated Ca2+ release from intracellular stores. In
agreement with this, we observe, in the megakaryocytic Dami
cells, that downregulation of RGS18 by RNA interference strongly
increases intracellular Ca2+ release as early as the concentration of
0.1 UI/ml of thrombin (Figure S9). Altogether these data suggest
that RGS18 might control calcium signaling to limit platelet
activation by attenuating Gq signaling pathways in platelets, in
particular that of PAR receptors.
In conclusion, by generating RGS18 knockout mice for the first
time and describing their phenotype, we have helped to advance
in the understanding of the role of RGS proteins on MK
differentiation and platelet generation in vivo. RGS proteins play
essential regulatory roles in the signaling of G protein-coupled
receptors and display remarkable specificity and selectivity in their
regulation of GPCR-mediated physiological events. GPCRs
constitute the largest family of receptors in the genome and are
the targets for at least 50% of current medicines. For many G
protein-coupled receptors, intense efforts to develop orthosteric
drugs have failed to yield highly selective ligands. In recent years,
major advances have been made and established allosteric GPCR
modulators as a novel approach to regulate this important class of
drug targets. In particular, these allosteric modulators have
provided novel tools and drug leads for multiple receptors for
which efforts aimed at discovery of orthosteric ligands had been
unsuccessful. In parallel, research data have highlighted RGS
proteins as attractive targets for the development of potential
future therapeutics that would control GPCR signaling in a tissue-
or pathway-specific manner. Here we have demonstrated the
functional importance of endogenous RGS18 in vivo, showing
that RGS18 is a key regulator of GPCR signaling in MKs and
platelets, controlling both platelet generation and platelet function.
Numerous RGS knockout mice have been generated [37]. These
models have provided essential information for our understanding
of the physiological role of RGS proteins but in many cases,
reported effects are modest [38,39]. In the present study, we
describe readily detectable effects in RGS18-deficient mice but
nevertheless with only a mild phenotype. The most likely
explication is a functional redundancy with other RGS proteins.
It is evident that at least RGS10 and RGS16 present some degree
of functional redundancy with RGS18 in vitro in platelets and
megakaryocytes, respectively [31,34,13]; which might partially
compensate for RGS18 deficiency in the different cellular contexts
and thus explaining the minimal phenotype observed in mutant
mice. From a clinical perspective, it is not clear whether increasing
RGS18 function could protect from cardiovascular or hematolog-
ical diseases. Yet what can be said at this point with some degree of
assurance is that enhancers rather than inhibitors may be more
useful in RGS18 drug development; emerging data show
reductions in RGS protein expression or function in several
pathophysiological states, and strategies to increase RGS function
are now emerging [40].
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